64 related articles for article (PubMed ID: 1363723)
1. Expression of P-glycoprotein on normal lymphocytes: enhancement of the doxorubicin-sensitivity of concanavalin A-responding mouse spleen cells by P-glycoprotein blockers.
Pourtier-Manzanedo A; Didier A; Loor F
Oncol Res; 1992; 4(11-12):473-80. PubMed ID: 1363723
[TBL] [Abstract][Full Text] [Related]
2. Atypical multi-drug resistance (MDR): low sensitivity of a P-glycoprotein-expressing human T lymphoblastoid MDR cell line to classical P-glycoprotein-directed resistance-modulating agents.
Jachez B; Loor F
Anticancer Drugs; 1993 Dec; 4(6):605-15. PubMed ID: 7905300
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein expression and activity of resistance modifying agents in primary cultures of human renal and adrenocortical carcinoma cells.
Fridborg H; Larsson R; Juhlin C; Rastad J; Akerström G; Backlin K; Nygren P
Anticancer Res; 1994; 14(3A):1009-16. PubMed ID: 7915506
[TBL] [Abstract][Full Text] [Related]
4. Myeloid and lymphoid cell alterations in normal mice exposed to chemotherapy with doxorubicin and/or the multidrug-resistance reversing agent SDZ PSC 833.
Froidevaux S; Loor F
Int J Cancer; 1994 Oct; 59(1):133-40. PubMed ID: 7927893
[TBL] [Abstract][Full Text] [Related]
5. Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446.
Jachez B; Nordmann R; Loor F
J Natl Cancer Inst; 1993 Mar; 85(6):478-83. PubMed ID: 8095304
[TBL] [Abstract][Full Text] [Related]
6. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.
Boesch D; Gavériaux C; Jachez B; Pourtier-Manzanedo A; Bollinger P; Loor F
Cancer Res; 1991 Aug; 51(16):4226-33. PubMed ID: 1678313
[TBL] [Abstract][Full Text] [Related]
7. Overcoming PGP-related multidrug resistance. The cyclosporine derivative SDZ PSC 833 can abolish the resistance to methoxy-morpholynil-doxorubicin.
Michieli M; Damiani D; Michelutti A; Melli C; Ermacora A; Geromin A; Fanin R; Russo D; Baccarani M
Haematologica; 1996; 81(4):295-301. PubMed ID: 8870372
[TBL] [Abstract][Full Text] [Related]
8. Extent and persistence of P-glycoprotein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents.
Boesch D; Loor F
Anticancer Drugs; 1994 Apr; 5(2):229-38. PubMed ID: 7914109
[TBL] [Abstract][Full Text] [Related]
9. SDZ PSC-833--a novel potent in vitro chemosensitizer in multiple myeloma.
Jonsson B; Nilsson K; Nygren P; Larsson R
Anticancer Drugs; 1992 Dec; 3(6):641-6. PubMed ID: 1363199
[TBL] [Abstract][Full Text] [Related]
10. SDZ 280-446, a novel semi-synthetic cyclopeptolide: in vitro and in vivo circumvention of the P-glycoprotein-mediated tumour cell multidrug resistance.
Loor F; Boesch D; Gavériaux C; Jachez B; Pourtier-Manzanedo A; Emmer G
Br J Cancer; 1992 Jan; 65(1):11-8. PubMed ID: 1346365
[TBL] [Abstract][Full Text] [Related]
11. Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines.
van der Graaf WT; de Vries EG; Timmer-Bosscha H; Meersma GJ; Mesander G; Vellenga E; Mulder NH
Cancer Res; 1994 Oct; 54(20):5368-73. PubMed ID: 7923167
[TBL] [Abstract][Full Text] [Related]
12. SDZ PSC 833 and SDZ 280-446 are the most active of various resistance-modifying agents in restoring rhodamine-123 retention within multidrug resistant P388 cells.
Pourtier-Manzanedo A; Didier AD; Muller CD; Loor F
Anticancer Drugs; 1992 Aug; 3(4):419-25. PubMed ID: 1421439
[TBL] [Abstract][Full Text] [Related]
13. Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia.
Colombo T; Gonzalez Paz O; D'Incalci M
Br J Cancer; 1996 Apr; 73(7):866-71. PubMed ID: 8611397
[TBL] [Abstract][Full Text] [Related]
14. SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia.
Keller RP; Altermatt HJ; Nooter K; Poschmann G; Laissue JA; Bollinger P; Hiestand PC
Int J Cancer; 1992 Feb; 50(4):593-7. PubMed ID: 1347037
[TBL] [Abstract][Full Text] [Related]
15. SDZ 280-125: a cyclopeptolide endowed with an in vitro cyclosporin A-like profile of activity for the reversion of the P-glycoprotein-mediated multidrug resistance of tumor cells.
Jachez B; Boesch D; Emmer G; Loor F
Anticancer Drugs; 1994 Jun; 5(3):313-20. PubMed ID: 7919456
[TBL] [Abstract][Full Text] [Related]
16. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Xu HB; Li L; Liu GQ
Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein expression and in vitro reversion of doxorubicin resistance by verapamil in clinical specimens from acute leukaemia and myeloma.
Solary E; Bidan JM; Calvo F; Chauffert B; Caillot D; Mugneret F; Gauville C; Tsuruo T; Carli PM; Guy H
Leukemia; 1991 Jul; 5(7):592-7. PubMed ID: 1677057
[TBL] [Abstract][Full Text] [Related]
18. Avoidance of doxorubicin resistance in osteosarcoma cells using a new quinoline derivative, MS-209.
Takeshita H; Kusuzaki K; Tsuji Y; Hirata M; Hashiguchi S; Nakamura S; Murata H; Ashihara T; Hirasawa Y
Anticancer Res; 1998; 18(2A):739-42. PubMed ID: 9615713
[TBL] [Abstract][Full Text] [Related]
19. Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833.
Michieli M; Damiani D; Michelutti A; Candoni A; Masolini P; Scaggiante B; Quadrifoglio F; Baccarani M
Haematologica; 1994; 79(6):500-7. PubMed ID: 7896208
[TBL] [Abstract][Full Text] [Related]
20. Direct interaction between verapamil and doxorubicin causes the lack of reversal effect of verapamil on P-glycoprotein mediated resistance to doxorubicin in vitro using L1210/VCR cells.
Breier A; Drobná Z; Barancík M
Neoplasma; 1998; 45(4):248-53. PubMed ID: 9890669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
